Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Eduardo Pennella, MD +1 617 401 4499
USenquiries@merus.nl


David Yao, MD +1 617 401 4499
USenquiries@merus.nl


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Back

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Recruiting

Open to: ALL

Age: 18.0 - N/A

Liverpool London Sutton Manchester Cambridge Middlesex London London London Glasgow Cardiff Newcastle upon Tyne

Medical Conditions

Head and Neck Squamous Cell Carcinoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2024 Feb 2028

Publications

"Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13."; "40511820"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : MCLA-158

Intervention Arm Group : MCLA-158;

Intervention Type : DRUG
Intervention Description : Cetuximab

Intervention Arm Group : Investigator's Choice;

Intervention Type : DRUG
Intervention Description : Methotrexate

Intervention Arm Group : Investigator's Choice;

Intervention Type : DRUG
Intervention Description : Docetaxel

Intervention Arm Group : Investigator's Choice;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Site 44
    Liverpool
    L7 8YA
  • Site 42
    London
    SW3 6JJ
  • Site 43
    Sutton
    SM2 5PT
  • Site 48
    Manchester
    M20 4BX
  • Site 65
    Cambridge
    CB2 0QQ
  • Site 70
    Middlesex
    HA6 2RN
  • Site 90
    London
    SE1 9RT
  • Site 140
    London
    EC1A 7BE
  • Site 157
    London
    E20 1JQ
  • Site 171
    Glasgow
    G12 0YN
  • Site 174
    Cardiff
    CF14 2TL
  • Site 191
    Newcastle upon Tyne
    NE7 7DN

Eduardo Pennella, MD +1 617 401 4499
USenquiries@merus.nl


David Yao, MD +1 617 401 4499
USenquiries@merus.nl



The study is sponsored by Merus B.V.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06496178
Last updated 19 February 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top